Third-line enfortumab vedotin improved outcomes in metastatic urothelial carcinoma, per real-world data from the EV-301 trial ...

Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.

Future directions for ctDNA in the preoperative setting involve assaying circulating or urinary cell-free DNA through NGS after UTUC diagnosis. This approach aims to improve accurate staging and ...

Accurately diagnosing and staging patients with upper tract urothelial carcinoma (UTUC) has proven challenging for clinicians. Experts at Memorial Sloan Kettering recently applied genomic ...

Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical ...

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...

Cxbladder Monitor accurately rules out recurrent urothelial carcinoma ... patients likely to have high-grade or late-stage bladder cancer. When selecting exclusively for high-grade or late ...

One of its most peculiar characteristics is a strong association with upper urothelial cancer (UUC). BEN-related UUC has the same histological features as other forms of UUC in general ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his abdomen after drinking water. It was just a fleeting moment; one he brushed ...

Scott T. Tagawa, MD, emphasizes the importance of new data from ASCO 2024 on enfortumab vedotin (EV) for managing advanced urothelial carcinoma, highlighting the importance of dose intensity and ...